@misc{indiciaef901941b6186,
  title = {Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction},
  author = {England, E. and Rees, D. G. and Scott, I. C. and Carmen, S. and Chan, D. T. Y. and Huntington, C. E. C. and Houslay, K. F. and Erngren, T. and Penney, M. and Majithiya, J. B. and Rapley, L. and Sims, D. A. and Hollins, C. and Hinchy, E. C. and Strain, M. D. and Kemp, B. P. and Corkill, D. J. and May, R. D. and Vousden, K. A. and Butler, R. J. and Mustelin, T. and Vaughan, T. J. and Lowe, D. C. and Colley, C. and Cohen, E. S.},
  year = {2023},
  doi = {10.1101/2023.02.28.527262},
  url = {https://www.biorxiv.org/content/10.1101/2023.02.28.527262v1},
  note = {Source identifier: 10.1101/2023.02.28.527262}
}